Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent hepatitis b vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics
01
Overview
This entry refers to a vaccination regimen or set of vaccines evaluated in a Phase 2 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The regimen involves the administration of a monovalent hepatitis B vaccine and the pentavalent combination vaccine Pediarix (DTaP-HepB-IPV). Pediarix, developed by GSK and FDA-approved in 2002, provides active immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. The NIAID study (NCT00328848) specifically assessed the safety and immunogenicity of an alternative schedule—administering the vaccines at birth, 2, and 6 months—compared to the standard routine infant schedule in healthy neonates.
- Brand names
- Pediarix
- Other names
- DTaP-HepB-IPV + HepB vaccinemonovalent hepatitis b vaccine + Pediarix
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)
Beyond the preview
Go deeper on monovalent hepatitis b vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent hepatitis b vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis.